Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Lin JJ, Choudhury NJ, Yoda S, Zhu VW, Johnson TW, Sakhtemani R, Dagogo-Jack I, Digumarthy SR, Lee C, Do A, Peterson J, Prutisto-Chang K, Malik W, Hubbeling HG, Langenbucher A, Schoenfeld AJ, Falcon CJ, Temel JS, Sequist LV, Yeap BY, Lennerz JK, Shaw AT, Lawrence MS, Ou SI, Hata AN, Drilon A, Gainor JF. Lin JJ, et al. Among authors: falcon cj. Clin Cancer Res. 2021 May 15;27(10):2899-2909. doi: 10.1158/1078-0432.CCR-21-0032. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685866 Free PMC article.
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers.
Choudhury NJ, Marra A, Sui JSY, Flynn J, Yang SR, Falcon CJ, Selenica P, Schoenfeld AJ, Rekhtman N, Gomez D, Berger MF, Ladanyi M, Arcila M, Rudin CM, Riely GJ, Kris MG, Heller G, Reis-Filho JS, Yu HA. Choudhury NJ, et al. Among authors: falcon cj. J Thorac Oncol. 2023 Apr;18(4):463-475. doi: 10.1016/j.jtho.2022.11.022. Epub 2022 Dec 6. J Thorac Oncol. 2023. PMID: 36494075 Free PMC article.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM; Princess Margaret Lung Group; Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Middha P, et al. Among authors: falcon cj. medRxiv [Preprint]. 2023 Sep 13:2023.05.15.23289680. doi: 10.1101/2023.05.15.23289680. medRxiv. 2023. PMID: 37292751 Free PMC article. Updated. Preprint.
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.
Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, Bivona TG, Wood KC. Ali M, et al. Among authors: falcon cj. Sci Transl Med. 2022 Mar 30;14(638):eabc7480. doi: 10.1126/scitranslmed.abc7480. Epub 2022 Mar 30. Sci Transl Med. 2022. PMID: 35353542 Free PMC article.
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis.
Middha P, Thummalapalli R, Betti MJ, Yao L, Quandt Z, Balaratnam K, Bejan CA, Cardenas E, Falcon CJ, Faleck DM; Princess Margaret Lung Group; Gubens MA, Huntsman S, Johnson DB, Kachuri L, Khan K, Li M, Lovly CM, Murray MH, Patel D, Werking K, Xu Y, Zhan LJ, Balko JM, Liu G, Aldrich MC, Schoenfeld AJ, Ziv E. Middha P, et al. Among authors: falcon cj. Nat Commun. 2024 Mar 26;15(1):2568. doi: 10.1038/s41467-023-44512-4. Nat Commun. 2024. PMID: 38531883 Free PMC article.
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy.
Kalchiem-Dekel O, Falcon CJ, Bestvina CM, Liu D, Kaplanis LA, Wilhelm C, Eichholz J, Harada G, Wirth LJ, Digumarthy SR, Lee RP, Kadosh D, Mendelsohn RB, Donington J, Gainor JF, Drilon A, Lin JJ. Kalchiem-Dekel O, et al. Among authors: falcon cj. J Thorac Oncol. 2022 Sep;17(9):1130-1136. doi: 10.1016/j.jtho.2022.06.008. Epub 2022 Jul 2. J Thorac Oncol. 2022. PMID: 35788405 Free PMC article.
Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors.
Solomon JP, Yang SR, Choudhury NJ, Ptashkin RN, Eslamdoost N, Falcon CJ, Martin A, Plodkowski A, Wilhelm C, Shen R, Ladanyi M, Berger M, Zhang Y, Drilon A, Arcila ME. Solomon JP, et al. Among authors: falcon cj. Clin Cancer Res. 2022 Nov 1;28(21):4649-4659. doi: 10.1158/1078-0432.CCR-22-1321. Clin Cancer Res. 2022. PMID: 36044468 Free PMC article.
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Choudhury NJ, Schoenfeld AJ, Flynn J, Falcon CJ, Rizvi H, Rudin CM, Kris MG, Arcila ME, Heller G, Yu HA, Ladanyi M, Riely GJ. Choudhury NJ, et al. Among authors: falcon cj. Clin Cancer Res. 2021 May 15;27(10):2920-2927. doi: 10.1158/1078-0432.CCR-20-4650. Epub 2021 Mar 8. Clin Cancer Res. 2021. PMID: 33685865 Free PMC article.
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski LA, Murray JC, Marrone KA, Scott SC, Houseknecht S, Falcon CJ, Evans P, Feliciano J, Hann CL, Ettinger DS, Smith KN, Anagnostou V, Forde PM, Brahmer JR, Levy B, Drilon A, Lam VK. Nakazawa M, et al. Among authors: falcon cj. Cancer Res Commun. 2024 Mar 14;4(3):786-795. doi: 10.1158/2767-9764.CRC-24-0065. Cancer Res Commun. 2024. PMID: 38407352 Free PMC article.
11 results